Markets UTHR

United Therapeutics Buys Thymmune Therapeutics

July 02, 2026 — 06:49 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - United Therapeutics Corp. (UTHR) on Thursday announced the acquisition of privately held Thymmune Therapeutics for up to $300 million.

The transaction includes $140 million in cash at closing.

Former Thymmune equityholders are also eligible to receive up to $160 million in earn-out payments upon the achievement of specified clinical and regulatory milestones through the end of 2031.

The company said the acquisition strengthens its regenerative medicine and transplant platform by expanding its capabilities in immunomodulatory therapies.

The acquisition adds Thymmune's preclinical regenerative thymic cell therapy platform to United Therapeutics' portfolio.

Thymmune's lead candidate, THY-100, is being developed for congenital athymia, a rare condition in which infants are born without a functional thymus.

On Wednesday, United Therapeutics Corp. closed trading 0.98% higher at $547.15 on the Nasdaq.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
UTHR

Latest Articles
Data is currently not available